Kornimate/medical-research-clean huggingface dataset:
restoring walking with a powered exoskeleton after spinal cord injury

Conditions: Spinal Cord Injury

Summary: powered exoskeletons have emerged recently, promising to offer walking to individuals with severe spinal cord injury who are unable to walk. we will use the rewalk exoskeleton to train walking in individuals with chronic, severe spinal cord injury (sci). we will determine the characteristics of individuals who most benefit from such training, and identify the neuroplasticity induced by the training. we will further determine the feasibility of the rewalk for home and community ambulation.

a prospective, pilot, cohort study design will recruit participants to train intensively for a 3 month period. the training sessions will be documented in detail, including number of steps taken, speed of walking, distance of walking. once walking speed has plateaued, we will evaluate the feasibility of using the device in a home-like environment and in the community. at the end of this study, we will have a good idea of the capability of the rewalk to assist walking in those with severe spinal cord injury. we will better understand which individuals are most likely to benefit from the rewalk. we will know how training in the rewalk changes the neural connections between the brain and the spinal cord so that we can better guide the training protocol. finally, we will identify limitations of the rewalk for home and community use, so that exoskeletons can be improved in the future to maximize their benefit to people with spinal cord injury.

Eligibility criteria:
inclusion criteria: * non-progressive spinal cord injury ≥1 year post-injury * body height between 5'3" and 6'4" * body weight ≤82 kg * uses wheelchair as primary mode of mobility * if able to walk, walks at ≤0.4 m/s * arm strength sufficient to control forearm crutches * agree to attend intensive training of 1.5 hr/day, 4 days/wk for 14 weeks, plus testing pre and post training of approximately 2 weeks each exclusion criteria: * contractures at the hip, knee or ankle that interferes with fitting into the rewalk * fractures within the last 2 years * osteoporosis in the legs (t-score ≤-3.0) * severe postural hypotension * severe spasticity that interferes with use of the rewalk * active pressure sores * pregnancy * severe head injury * conditions that preclude intensive exercise (such as high blood pressure) * presence of conditions contraindicated for transcranial magnetic stimulation

Keywords: walking locomotion rehabilitation
cpap versus hfno for the treatment of acute hypoxemic respiratory failure due to community acquired pneumonia

Conditions: Pneumonia; Respiratory Failure

Summary: the study compares two non-invasive respiratory support modalities ie cpap and high flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to community acquired pneumonia.

cpap and high flow nasal cannula oxygen are two established modalities for non-invasive respiratory support . in covid pandemic era both cpap and hfno were widely used in the ward for the treatment of covid-19 induced acute hypoxemic respiratory failure in order to prevent progression to intubation. head to head comparison between the two modalities mentioned for the treatment of severe hypoxemic respiratory failure is not available neither in covid pneumonia or community acquired pneumonia (cap).

Eligibility criteria:
inclusion criteria: * adult patients with age \>18 year old. * been hospitalized with community acquired pneumonia * hospitalized in common ward (not icu) * patients should have pneumonia- pulmonary infiltrates in chest-xray and hypoxemic respiratory failure. * patients should be unable to keep: spo2\>93% with fio2 50%, or spo2 95% with fio2 50% and have evidence of respiratory distress defined as respiratory rate -rr\>35/min exclusion criteria: * need for immediate or imminent intubation * not fit for escalation of treatment: defined as intubation, mechanical ventilation and icu support. * pregnant women * contraindication to cpap or hfno

Keywords: cpap hfno
stem cell infusion in the treatment of patients with neurological sequelae after ischemic stroke

Conditions: Ischemic Stroke

Summary: this trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived mscs (uc-mscs) in combination with standard neurological complications after ischemic stroke treatment in vietnam.

stroke is the second leading cause of death behind ischemic heart disease worldwide. traditional treatments have some limitations whereas preclinical data suggest that stem cell therapy is a promising regenerative medical treatment given the limited capacity of the central nervous system for self-repairs after ischemic stroke. previous studies have shown that umbilical cord blood-derived mesenchymal stem cell (uc-msc) infusion improves the outcomes of several neurological damage conditions, including stroke. these results encouraged us to initiate the phase i/ii clinical trial aiming to evaluate the safety and the efficiency of uc-msc transplantation in the treatment of patients with neurological complications after ischemic stroke. this case-control phase i/ii trial is conducted at vinmec times city international hospital, hanoi, vietnam between 2021 and 2023. in this trial, 48 patients with neurological complications after ischemic stroke will be enrolled into 3 groups: uc-msc infusion via intravenous route group (16), uc-msc infusion via intrathecal administration route group (16), and control group (16). the uc-msc group (iv/intrathecal) will receive two doses of thawed uc-msc product at 1.5x106 cells/kg patient body weight with an intervention interval of three months. the primary outcome measures will include the incidence of prespecified administration-associated adverse events (aes) and serious adverse events (saes). the potential efficacy will be measured using these scales including national institutes of health stroke scale-nihss, functional independence measure -fim, modified ashworth scale-mas, fine motor skills-fms, 36-item short form survey -sf-36. the clinical evaluation will be conducted at baseline and 3-, 6- and 12-months post-intervention.

Eligibility criteria:
* age: from 40 to 75 years. * gender: either sex * patients have been discharged/patients who are hospitalized but their general condition is stable: * no need for vasopressor drugs * no need for mechanical ventilation or oxygen support * no signs of infection (fever, high wbc, high crp/procalcitonin) * no kidney failure, liver failure, heart failure. * time from onset to study participation ≤ 24 months * national institutes of health stroke scale (nihss) score \>=5 * agree to participate in the study exclusion criteria: * hematologic cause of stroke * there is evidence of active infections, failure of heart, lung, liver, or kidney, respiratory distress syndrome, anemia, clotting disorder * cancer. * pregnancy. * tracheostomy, coma, complete quadriplegia, vegetative.

Keywords: ischemic stroke umbilical cord mesenchymal stem cells neurological complication
platelets to lymphocytes ratio in sepsis

Conditions: Platelets to Lymphocytes Ratio Sepsis

Summary: the aim of this study is to compare effectiveness of platelets to lymphocytes ratio (plr) with procalcitonin as a predictor of sepsis outcome.

sepsis is a rapidly progressive, life-threatening disease. accurate and expeditious assessment of sepsis is important for early administration of antibiotics and removal of the source of infection. in the 2016 version of the sepsis guidelines (sepsis-3), the concept of the systemic inflammatory response syndrome has been deleted. although most patients with sepsis receive intensive management, such as early goal directed therapy (egdt), in an emergency department (ed), the mortality rate of sepsis has been reported to be greater than 20% to 30%. many clinicians have studied the usefulness of blood biomarkers such as c-reactive protein, procalcitonin, and lactate for early assessment of sepsis and for prognostication, in order to initiate timeous treatment and to prevent rapid progression to multi-organ failure. several studies mentioned the advantages of the precursor molecule of calcitonin, namely procalcitonin as a biomarker for sepsis. in recent years, studies have reported that platelets and lymphocytes play critical roles in the inflammatory process. therefore, the platelet-to-lymphocyte ratio (plr) a novel inflammatory factor has received research attention recently, as it may act as an indicator of inflammation, in a wide spectrum of diseases, such as myocardial infarction,acute kidney injury (aki), based on the findings of previous studies, it is reasonable to speculate the presence of a potential relationship between plr and mortality for sepsis. platelet to lymphocytes ratio is defined as the ratio of the absolute platelet count and absolute lymphocyte count.

Eligibility criteria:
inclusion criteria: 1. septic patients according to third international consensus definitions for sepsis 2. with icu stay more than 24 hours will be included. exclusion criteria: 1. pregnant and women in puerperium. 2. patients with active hemorrhage 3. patients with hematological diseases (including bone marrow diseases) and collagen diseases. 4. patients on corticosteroid therapy or immunosuppressive drugs. 5. patients who will need immediate surgical interventions. 6. acute cerebrovascular or coronary syndrome. 7. patients received blood or platelets transfusion before enrollment in the study.
effect of surface sealant application on clinical performance occlusal restorations

Conditions: Dental Caries; Class I Dental Caries; Dental Composite

Summary: the aim was to evaluate the clinical performance of hema-containing and hema-free all-in-one self-etch adhesives with and without a surface sealing process with a nanohybrid composite in occlusal caries restorations. the hypothesis is that the hema-containing and hema-free all-in-one self-etch adhesive and the surface sealing process would significantly effect clinical performance of occlusal restorations.


Eligibility criteria:
inclusion criteria: * patients who received four direct class i composite restorations, those with good oral hygiene with no active periodontal or pulpal diseases, whose permanent first or second molar required restorations for occlusal carious lesions with neighboring teeth and were in occlusion with antagonist teeth, and were willing to return for follow-up examinations as outlined by the investigators. exclusion criteria: * patients with uncontrolled parafunction, those presenting with poor oral hygiene and disinterested in or refused oral hygiene instructions, molars and premolars with carious lesions on a surface other than the occlusal surface and in continuity with the occlusal cavity, pulp exposure during caries removal procedure or cavities with the risk of pulp exposure, having spontaneous pain or sensitivity to percussion, and patients with periodontal or gingival disease.
a policy relevant us trauma care system pragmatic trial for ptsd and comorbidity pilot

Conditions: Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life

Summary: the goal of this pilot study is to develop and implement a larger scale, multi-site stepped collaborative care trial that targets injured patients with presentations of posttraumatic stress disorder (ptsd) and related comorbidities.


Eligibility criteria:
inclusion criteria: * inpatient/emergency admission for traumatic injury exclusion criteria: * non-english speaking * self-inflicted injury * actively psychotic * incarcerated or in custody
study on the efficacy and mechanism of mettl3 peptide inhibitors in enhancing anti-tumor immune response by reshaping the tumor microenvironment

Conditions: Bladder Cancer; Prostate Cancer; Kidney Cancer

Summary: this study aims to validate the accuracy and clinical value of mettl3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with urinary system tumors through pathological examination; 2. meet specific clinical stages and surgical treatment standards; 3. intraoperative tissue resection meets the sample testing standards; 4. the patient is willing to participate in the study and sign an informed consent form. exclusion criteria: 1. not meeting the specific clinical stage and not receiving surgical treatment; 2. abnormal mental behavior; 3. intellectual disability; 4. age under 18 years old or over 75 years old; 5. low understanding and communication skills.
prospective study of head and neck cancer radiation treatment with or without amifostine

Conditions: Oral Mucositis; Stomatitis

Summary: the purpose of this study is to compare the incidence of stomatitis when treating with amifostine before radiation treatment.


Eligibility criteria:
inclusion criteria: 1. 18-70 years old, male or female 2. primary treatment of phase i-iva head and neck cancer patients, identified by histological and pathological diagnosis 3. postoperative patients should receive radiation treatment in 12 weeks 4. ecog \<2 5. expected lifetime ≥6months 6. no severe complications (hypertension, chd, diabetes and psychiatric history, etc.) 7. not involved in other clinical trials 8. sign icf exclusion criteria: 1. ecog \>2 2. suffered other cancers in the past 5 years 3. received amifostine treatment in the past 4 weeks 4. unable to complete treatment or sign icf because of medical or physical reasons

Keywords: identify whether cytofos can reduce the incidence and duration of hnc patients' oral mucositis caused by radiotherapy.
long-term follow-up study with darvadstrocel in the treatment of complex perianal fistula

Conditions: Crohn's Disease; Complex Perianal Fistula

Summary: the main aim is to follow-up on long term side effect and symptom improvement of darvadstrocel in the treatment of complex perianal fistula in adults. participants will not receive any drug in this study.

the drug being tested in this study is called darvadstrocel (cx601). darvadstrocel is being tested to treat people who have complex perianal fistula in cd. this study will look at the long-term safety and efficacy of darvadstrocel in the treatment of complex perianal fistula in cd. the study will enroll approximately 150 patients. participants who received darvadstrocel or placebo in study admire-cd ii (cx601-0303, nct03279081) and who have completed the 52 weeks of the study will be enrolled in this long-term extension study. this multi-center study will be conducted worldwide. the overall time to participate in this study is 104 weeks (in addition to the 52 weeks on admire-cd ii study). participants will make multiple visits to the clinic and will be contacted by telephone every 3 months for a follow-up assessment. after unblinding of the admire-cd ii study, the lte study will be conducted as an open-label study. participants will remain in the treatment group assigned in the admire-cd ii study.

Eligibility criteria:
inclusion criteria: 1. has participated in and completed the admire-cd ii (nct03279081) study (i.e., did not discontinue). exclusion criteria: 1. has been more than 3 months since the participant completed the admire-cd ii study.

Keywords: drug therapy
evaluation of pandemic vaccination campaign

Conditions: Influenza Caused by the Novel A(H1N1)v Influenza Virus

Summary: a cohort of 4000 community-dwelling adults is followed to evaluate the effectiveness of the finnish national a(h1n1)v influenza vaccination campaign in preventing the first episode of laboratory-confirmed a(h1n1)v influenza. the safety of vaccination and the severity of the disease are followed primarily from health care registers. in a subgroup of 200 participants, the humoral and cellular immunogenicity of the vaccine will be studied.


Eligibility criteria:
inclusion criteria: * full legal competence; * written informed consent obtained; * assigned to use the services of tampere health centre and community-dwelling; * at least 18 and no more than 75 years old, inclusive; * belongs to the target group of a(h1n1)v vaccination in the region during the pandemic vaccination campaign; * able to communicate fluently in finnish or swedish * able to adhere to all protocol required study procedures without any special burden or risk, as judged by the investigator or designate. exclusion criteria: * for the total study cohort, no specific exclusion criteria will be applied; * for the subgroup for follow-up of immunogenicity of the vaccine (immunogenicity cohort), exclusion criteria comprise: * previous severe allergic reaction to influenza vaccines or known severe allergy to the ingredients of the vaccine * previous severe allergic reaction to eggs * significant immunological disorder

Keywords: a(h1n1)v influenza vaccination pandemic
musculoskeletal disorders in mountain runners

Conditions: Musculoskeletal Diseases

Summary: the study aims to estimate the prevalence of musculoskeletal disorders in a population of runners in the mountains; moreover it proposes to explore the relationship between distance traveled, the difference in height, the training frequency in the week, the shoes worn, the training method, the use of supports and experience of running with musculoskeletal disorders. the secondary objectives of this study are to investigate to which rehabilitative figures the sportsman turns and if the treatments have positive outcomes.

running is one of the most popular forms of exercise in the world. the prevalence of musculoskeletal disorders in street runners has already been extensively studied and is about 55% of those affected. in recent years, more and more runners paid their attention to mountain running where, the different types of terrain and the important differences in height require a different musculoskeletal effort. in the literature there are few studies that have investigated the prevalence of disorders, risk factors and protective factors on these runners. the mountain running performed with regularity and method is certainly a healthy activity for individuals, but it is not free from injuries due to several factors, such as long distance, significant differences in level and uneven terrain. it is not clear whether these factors can influence the onset of skeletal muscle disorders. the study aims to estimate the prevalence of musculoskeletal disorders in this population of mountain runners; moreover it proposes to explore in this population the relationship between distance traveled, the difference in height, the training frequency in the week, the shoes worn, the training method, the use of supports and experience of running with musculoskeletal disorders. moreover, the study wants to investigate to which rehabilitative figures the sportsman turns and if the treatments have positive outcomes. inclusion criteria are: age over 18, be a participant of at least one trail, understand the italian language, to have signed informed consent. recruitment: all participants in mountain races will be invited to reply to the attached questionnaire anonymously when the race bib is picked up. the runners will be free to participate or not in the survey, without the choice can affect the results of the race in any way and can create situations of subjection to the organization.

Eligibility criteria:
inclusion criteria: * age over 18, * be a participant of at least one mountain race * understand the italian language * have signed an informed consent exclusion criteria: * under the age of 18 * do not understand italian language * not having given consent

Keywords: running resistance training mountain physiotherapy
effect of incretin-related drugs on dietary intake in japanese patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: it is well known that incretin, particular glp-１enhances satiety and reduces energy intake in controlling appetite and dietary in humans (flint a, et al. gutzwiller jp et al.). recently, incretin-based therapy has been attracted a lot of interest (hare kj, knop fk). however, it is not clear how the incretin-based therapy affects energy and content of dietary intake in patients with type 2 diabetes mellitus (t2dm). previously, the investigators reported the amount of energy and content of dietary intake in type 2 diabetic japanese patients with more than 10 years of long time duration after discovery using questionnaire (inoue k et al.) and the patients were impaired a secretion of active glp-1 (kamoi et al). the investigators examine whether the incretin-based therapy effects on the energy and content of dietary intake in the same patients before and one year after administration of incretin-related drugs using the same method previously (inoue k et al.).


Eligibility criteria:
inclusion criteria: * japanese patients with t2dm without incretin-based therapy, who participated to examine the energy and content of intake using questionnaire reported previously. exclusion criteria: * patients with a serious complication in the heart, liver or kidney * pregnant or possibly pregnant patients or lactating patients * patients complicated with a malignant tumor at present. * patients participating in other clinical study. * other than the above, patients judged inappropriate as the subjects of this study by the investigator
study of home-embedded palliative care for hemodialysis-dependent end-stage renal disease

Conditions: End-Stage Renal Disease

Summary: home palliative care needs are often under-recognized in patients with end-stage renal disease (esrd). this pilot study is designed to evaluate the feasibility and acceptability of an initiative to enhance referrals to penn home palliative care compared with usual care among hemodialysis-dependent esrd patients admitted to a penn hospital. results will inform a future pragmatic trial comparing the effectiveness of home palliative care compared with usual care among esrd patients. evaluating the effectiveness of home palliative care services is critical to determine whether increasing access to these services would improve patient-centered outcomes for these high-need patients.


Eligibility criteria:
inclusion criteria: * be an adult (18 years of age or older) hospitalized at one of two study hospitals * digital signature of esrd (n18.6) within the last 12 months with an inpatient hemodialysis order * patient resides in the five-county area surrounding philadelphia which is served by the penn home palliative care services. * appropriate for home palliative care, defined as: (i) existing home care eligibility/referral for home care or (ii) severe protein malnutrition (e43, e44) or (iii) non-ambulatory status determined by a flowsheet completed by nursing on hospital admission with three ambulatory options: (1) non-ambulatory, (2) ambulates with assistance, or (3) ambulates independently. if this information is missing from the electronic health record, the determination will be made using one of the three following options: (1) overall prior home mobility assessment "complete dependence on all aspects," or (2) ambulation or functional transfers domains indicate "dependent," or (3) wheelchair mobility domain was completed (with any non-null/non-empty value). exclusion criteria: * none

Keywords: palliative esrd